Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its Chief Executive Officer, Vipin Garg, Ph.D., and Chief Medical Officer, Scott Harris, M.D., will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference:

Conference:	H.C. Wainwright 8thAnnual MASH Virtual Conference
Presenters:	Vipin Garg, Ph.D., Chief Executive Officer
	Scott Harris, M.D., Chief Medical Officer
Date/Time:	Monday, October 7, 2024, at 11:30 a.m. EDT

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Company Contact:Vipin GargPresident and Chief Executive OfficerPhone: [e-mail]

Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: [e-mail]

Investor Contact:Lee RothBurns McClellanPhone: [e-mail]

Julia WeilmanBurns McClellanPhone: [e-mail]

This press release was published by a CLEAR® Verified individual.